The U.S. Patent Applications Cover Proprietary Combinations of NeuroThera's PEA Technology With LSD, Ketamine and Ibogaine for Potential Therapeutic Applications, Including Mental Health Disorders, Such as Depression and PTSD as Well as Substance Use...
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi
Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate. Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second
Clearmind Medicine (CMND) said Friday it will acquire a 51% stake in Charging Robotics, which develo
U.S. Publication of a Patent Application Covering the MDMA-N-acylethanolamines Combination Expands Intellectual Property Generated Through the Collaboration, and Provides Guidance Addressing Clinical Development Considerations for Psychedelic Drugs, ...
This is the newest page. Registered accounts read further back.